Repeatability of cerebral perfusion using dynamic susceptibility contrast MRI in glioblastoma patients

Translational Oncology

Volumn 8, Issue 3, 2015, Pages 137-146

  Jafari Khouzani, Kourosh ^a   Emblem, Kyrre E ^a,b   Kalpathy Cramer, Jayashree ^a   Bjørnerud, Atle ^b,d   Vangel, Mark G ^a   Gerstner, Elizabeth R ^c   Schmainda, Kathleen M ^e   Paynabar, Kamran ^f   Wu, Ona ^a   Wen, Patrick Y ^g   Batchelor, Tracy ^c   Rosen, Bruce ^a   Stufflebeam, Steven M ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f Georgia Institute of Technology   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; CANCER GRADING; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DYNAMIC SUSCEPTIBILITY CONTRAST MAGNETIC RESONANCE IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MALE; MEASUREMENT REPEATABILITY; NUCLEAR MAGNETIC RESONANCE IMAGING;

EID: 84930700851     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2015.03.002     Document Type: Article

References (47)

1. [1] Villringer A, Rosen BR, Belliveau JW, Ackerman JL, Lauffer RB, Buxton RB, Chao YS, Wedeen VJ, and Brady TJ (1988). Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med 6(2), 164–174.
2. [2] Willats L and Calamante F (2012). The 39 steps: evading error and deciphering the secrets for accurate dynamic susceptibility contrast MRI. NMR Biomed 26(8), 913–931.
3. [3] Sorensen AG and Reimer P (2000). Cerebral MR Perfusion Imaging: Principlesand Current Applications. New York: Thieme; 2000.
4. [4] Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, and Hochberg FH, et al (1994). Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191(1), 41–51.
5. [5] Covarrubias DJ, Rosen BR, and Lev MH (2004). Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 9(5), 528–537.
6. [6] Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, and Hochberg FH, et al (2004). Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 25(2), 214–221.
7. [7] Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, and Kelly PJ (2006). Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 58(6), 1099–1107 [discussion-107].
8. [8] Gerstner ER, Sorensen AG, Jain RK, and Batchelor TT (2008). Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol 21(6), 728–735.
9. [9] Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, and Batchelor TT, et al (2012). Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72(2), 402–407.
10. [10] Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, and Rosen BR, et al (2013). Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 19(9), 1178–1183.
11. [11] Barnhart HX and Barboriak DP (2009). Applications of the repeatability of quantitative imaging biomarkers: a review of statistical analysis of repeat data sets. Transl Oncol 2(4), 231–235.
12. [12] Ellinger R, Kremser C, Schocke MF, Kolbitsch C, Griebel J, Felber SR, and Aichner FT (2000). The impact of peak saturation of the arterial input function on quantitative evaluation of dynamic susceptibility contrast-enhanced MR studies. J Comput Assist Tomogr 24(6), 942–948.
13. [13] Rausch M, Scheffler K, Rudin M, and Radu EW (2000). Analysis of input functions from different arterial branches with gamma variate functions and cluster analysis for quantitative blood volume measurements. Magn Reson Imaging 18(10), 1235–1243.
14. [14] Paulson ES and Schmainda KM (2008). Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 249(2), 601–613.
15. [15] Sakaie KE, Shin W, Curtin KR, McCarthy RM, Cashen TA, and Carroll TJ (2005). Method for improving the accuracy of quantitative cerebral perfusion imaging. J Magn Reson Imaging 21(5), 512–519.
16. [16] Knutsson L, Stahlberg F, and Wirestam R (2010). Absolute quantification of perfusion using dynamic susceptibility contrast MRI: pitfalls and possibilities. MAGMA 23(1), 1–21.
17. [17] Jackson A, Kassner A, Zhu XP, and Li KL (2001). Reproducibility of T2* blood volume and vascular tortuosity maps in cerebral gliomas. J Magn Reson Imaging 14(5), 510–516.
18. [18] Henry ME, Kaufman MJ, Lange N, Schmidt ME, Purcell S, Cote J, Perron-Henry DM, Stoddard E, Cohen BM, and Renshaw PF (2001). Test-retest reliability of DSC MRI CBV mapping in healthy volunteers. Neuroreport 12(8), 1567–1569.
19. [19] Shin W, Horowitz S, Ragin A, Chen Y, Walker M, and Carroll TJ (2007). Quantitative cerebral perfusion using dynamic susceptibility contrast MRI: evaluation of reproducibility and age- and gender-dependence with fully automatic image postprocessing algorithm. Magn Reson Med 58(6), 1232–1241.
20. [20] Grandin CB, Bol A, Smith AM, Michel C, and Cosnard G (2005). Absolute CBF and CBV measurements by MRI bolus tracking before and after acetazolamide challenge: repeatabilily and comparison with PET in humans. NeuroImage 26(2), 525–535.
21. [21] Lankester KJ, Taylor JN, and Stirling JJ, et al (2007). Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging 25(4), 796–805.
22. [22] Lankester KJ, Taylor JN, Stirling JJ, Boxall J, d'Arcy JA, Collins DJ, Walker-Samuel S, Leach MO, Rustin GJ, and Padhani AR (2010). Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. J Magn Reson Imaging 32(1), 155–164.
23. [23] Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA.
24. [24] Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, and Zhu M, et al (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1), 83–95.
25. [25] Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, and Benner T, et al (2010). Phase IIstudy of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28(17), 2817–2823.
26. [26] Weisskoff R, Boxerman J, and Sorensen A (1994). Simultaneous blood volume and permeability mapping using a single Gd-based contrast injection. Proceedings of the Twelfth Annual Meeting of the Society for Magnetic Resonance Imaging; 1994.
27. [27] Donahue KM, Krouwer HG, Rand SD, Pathak AP, Marszalkowski CS, Censky SC, and Prost RW (2000). Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 43(6), 845–853.
28. [28] Boxerman JL, Schmainda KM, and Weisskoff RM (2006). Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27(4), 859–867.
29. [29] Bjornerud A, Sorensen AG, Mouridsen K, and Emblem KE (2011). T1- and T2*-dominant extravasation correction in DSC-MRI: part I—theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab 31(10), 2041–2053.
30. [30] Mouridsen K, Christensen S, Gyldensted L, and Ostergaard L (2006). Automatic selection of arterial input function using cluster analysis. Magn Reson Med 55(3), 524–531.
31. [31] Bjornerud A and Emblem KE (2010). A fully automated method for quantitative cerebral hemodynamic analysis using DSC-MRI. J Cereb Blood Flow Metab 30(5), 1066–1078.
32. [32] Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, and Malkin MG (2014). Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro-Oncology 16(6), 880–888.
33. [33] Bedekar D, Jensen T, and Schmainda KM (2010). Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons. Magn Reson Med 64(3), 907–913.
34. [34] Emblem KE and Bjornerud A (2009). An automatic procedure for normalization of cerebral blood volume maps in dynamic susceptibility contrast-based glioma imaging. AJNR Am J Neuroradiol 30(10), 1929–1932.
35. [35] Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J, Sievers A, Yoon YH, Lee EJ, Yang MC, and Lewis RF, et al (2001). Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 19(2), 551–557.
36. [36] Avants BB, Epstein CL, Grossman M, and Gee JC (2008). Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 12(1), 26–41.
37. [37] Zhang Y, Brady M, and Smith S (2001). Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 20(1), 45–57.
38. [38] Shrout PE and Fleiss JL (1979). Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2), 420–428.
39. [39] Bland JM and Altman DG (1986). Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476), 307–310.
40. [40] Efron B and Tibshirani R (1993). An Introduction to the Bootstrap. New York: Chapman & Hall; 1993.
41. [41] Montgomery DC (2008). Design and analysis of experiments. 7th edn.Hoboken, NJ: Wiley; 2008.
42. [42] Benjamini Y and Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol, 289–300.
43. [43] Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J, Sievers A, Yoon YH, Lee EJ, Yang MC, and Lewis RF, et al (2014). Quantitative imaging biomarkers: a review of statistical methods for technical performance assessment. Stat Methods Med Res 24(1), 27–67.
44. [44] Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J, Sievers A, Yoon YH, Lee EJ, Yang MC, and Lewis RF, et al (2014). The emerging science of quantitative imaging biomarkers terminology and definitions for scientific studies and regulatory submissions. Stat Methods Med Res 24(1), 9–26.
45. [45] Yankeelov TE, Abramson RG, and Quarles CC (2014). Quantitative multimodality imaging in cancer research and therapy. Nat Rev Clin Oncol 11(11), 670–680.
46. [46] Troprès I, Pannetier N, Grand S, Lemasson B, Moisan A, Péoc'h M, Rémy C, and Barbier EL (2014). Imaging the microvessel caliber and density: principles and applications of microvascular MRI. Magn Reson Med 73(1), 325–341.
47. [47] Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, and Johnson G (2004). Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 25(5), 746–755.